List of Excipients in Branded Drug DIETHYLPROPION

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	DIETHYLPROPION HCL	diethylpropion hydrochloride	54868-1462	LACTOSE
Physicians Total Care Inc	DIETHYLPROPION HCL	diethylpropion hydrochloride	54868-1462	MAGNESIUM STEARATE
Physicians Total Care Inc	DIETHYLPROPION HCL	diethylpropion hydrochloride	54868-1462	STARCH, CORN
Physicians Total Care Inc	DIETHYLPROPION HCL	diethylpropion hydrochloride	54868-1462	TALC
Physicians Total Care Inc	DIETHYLPROPION HCL	diethylpropion hydrochloride	54868-1462	TARTARIC ACID

Generic Drugs Containing DIETHYLPROPION

Company	Ingredient	NDC	Excipient
Chartwell RX LLC	diethylpropion hydrochloride	62135-488	CELLULOSE, MICROCRYSTALLINE
Chartwell RX LLC	diethylpropion hydrochloride	62135-488	LACTOSE MONOHYDRATE
Chartwell RX LLC	diethylpropion hydrochloride	62135-488	MANNITOL
Chartwell RX LLC	diethylpropion hydrochloride	62135-488	POVIDONE
Chartwell RX LLC	diethylpropion hydrochloride	62135-488	TALC

What are the Most Frequently-Used Excipients in DIETHYLPROPION?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	LACTOSE MONOHYDRATE
1	MANNITOL
1	POVIDONE
1	TALC

Excipient Strategy and Commercial Opportunities for Diethylpropion

Last updated: February 25, 2026

Diethylpropion is an appetite suppressant marketed as an anti-obesity agent. It is marketed primarily under brand names such as Tenuate in the US, and several generic formulations. Its patent expiration has opened pathways for generic development, focusing on excipient optimization and formulation strategies to enhance market presence.

---

What Are the Core Excipient Strategies for Diethylpropion?

1. Formulation Optimization for Bioavailability and Stability

Diethylpropion is a stimulant of the phenethylamine class, requiring specific excipients to stabilize it and ensure consistent bioavailability. Typical excipient strategies include:

• Fillers and diluents: Microcrystalline cellulose and lactose are common to provide bulk and facilitate tablet compression.
• Disintegrants: Croscarmellose sodium or sodium starch glycolate, to ensure quick disintegration and absorption.
• Binders: Povidone or hydroxypropyl methylcellulose to improve tablet cohesion.

2. Ensuring Controlled Release and Reduced Side Effects

Modified-release formulations may incorporate:

• Coatings: Hydroxypropyl methylcellulose (HPMC) or ethylcellulose to modulate release and reduce gastrointestinal irritation.
• Polymer matrices: To sustain plasma levels, reducing tachyphylaxis and abuse potential.

3. Palatability and Patient Compliance

Though limited due to the drug’s intended oral route, excipients such as flavorings, sweeteners (sorbitol, aspartame), and lubricants enhance patient acceptance.

---

Opportunities for Formulation Development and Differentiation

1. Extended-Release (ER) Products

Developing ER formulations can provide:

• Once-daily dosing
• Improved patient adherence
• Reduced peak plasma fluctuations, potentially decreasing adverse events like hypertension and nervousness

Commercial Opportunity: ER diethylpropion formulation markets are underdeveloped, with existing products limited. Companies can leverage patents on controlled-release technologies to differentiate.

2. Combating Abuse Potential

Incorporating excipients that inhibit crushing (crush-resistant tablets) or using tamper-evident packaging can reduce misuse. Formulating with excipients that bind the drug tightly within the matrix limits manipulation.

3. Liquid and Chewable Forms

Liquid formulations for ease of ingestion or chewables for pediatric or elderly populations open niche markets but face challenges with stability and excipient safety profiles.

4. Combining with Other Agents

Fixed-dose combinations with antioxidants or adjuncts (e.g., caffeine to enhance efficacy) require excipient compatibility studies but expand therapeutic indications.

---

Commercial Opportunities and Market Considerations

Regulatory Landscape

• FDA approval pathways: Section 505(b)(2) for reformulations or combinations.
• Post-patent expiry: Generic manufacturers can compete on excipient stability, bioavailability, and cost.

Patent Landscape

Patent expirations (last US patent expired in 2018 [1]) have increased generic competition, requiring innovative excipient strategies to add differentiation.

Market Drivers

• Rising obesity prevalence: US obesity rate over 42% (CDC, 2020 [2])
• Demand for cost-effective treatment options
• Potential for market expansion via novel formulations

Challenges

• Narrow therapeutic window
• Side effect profile, including cardiovascular risks
• Limited patent protection

---

Summary of Formulation and Excipient Trends

Aspect	Typical Ingredients	Purpose	Opportunities
Immediate-release tablets	Microcrystalline cellulose, lactose, croscarmellose sodium	Disintegration, absorption	Competitive generics, cost reduction
Extended-release formulations	HPMC, ethylcellulose polymer coatings	Sustained release, reduced peaks	Market differentiation, patent strategies
Abuse-deterrent formulations	Crush-resistant excipients, tamper-evident packaging	Reduce misuse	Regulatory advantages
Liquid/chewable drugs	Flavors, sweeteners, lubricants	Patient adherence	Expanded patient populations

---

Key Takeaways

• Formulation strategies center on optimizing bioavailability, stability, and compliance.
• ER formulations and abuse-deterrent designs offer commercial differentiation.
• Patent expiry presents challenges but also opportunities through innovative excipient use.
• Obesity market growth fuels demand, but side effect management remains critical.
• Regulatory pathways favor reformulations and combination products to extend market life.

---

FAQs

Q1: What are the main challenges in formulating diethylpropion?
A1: Ensuring stability, controlling release to minimize side effects, and preventing abuse are primary challenges.

Q2: How can excipients help mitigate diethylpropion's side effects?
A2: Controlled-release excipients reduce peak plasma levels, lowering cardiovascular risks and nervousness.

Q3: Are there patent opportunities in diethylpropion formulations?
A3: Yes, developing ER, abuse-deterrent, or combination formulations can extend patent life through novel excipients.

Q4: How does the excipient strategy impact the cost of manufacturing?
A4: Simpler excipient matrices reduce costs; advanced coatings or tamper-evident features may increase manufacturing complexity.

Q5: What regulatory considerations influence excipient choice?
A5: Excipients must be FDA-approved for the specific route and patient population, especially for pediatric or elderly formulations.

---

References

[1] U.S. Patent No. 9,889,919. (2018).
[2] Centers for Disease Control and Prevention. (2020). Obesity prevalence among adults.